ENGN compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

ENGNenGene Therapeutics Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

ENGNenGene Therapeutics Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ENGN1 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+5.49%—

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedENGN realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

ENGNenGene Therapeutics Inc.

1.77▲+1.14%· post 1.77· delayed

Mkt cap$118.6MRevenue—Revenue—

AMGNAmgen Inc

465.26▲+1.05%· post 465.25· delayed

After hoursNov 9 '26delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

After hoursNov 9 '26delayed

ENGNenGene Therapeutics Inc.

AMGNAmgen Inc

1.77▲+1.14%post 1.77delayed

Price

465.26▲+1.05%post 465.25delayed

$118.6M

Mkt cap

$249.0B

—

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

ENGN1.77▲+1.14%vsAMGN465.26▲+1.05%After hoursNov 9 '26delayed